To access this element change to forms mode OFF
Grant Award View - GA89310
Evaluation of Fibroblastic Activation Protein Inhibitors (FAPI) as a...
GA ID:
GA89310
Agency:
Department of Health and Aged Care
Approval Date:
25-May-2020
Publish Date:
29-Jun-2020
Category:
Health and Medical Research
Grant Term:
1-Jun-2020 to 31-May-2025
Value (AUD):
$2,387,924.50
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 19/20 1.1 Health Policy Research and Analysis
Grant Program:
2019_MRFF_RCRDUN_RCRDUN_2020
Grant Activity:
Evaluation of Fibroblastic Activation Protein Inhibitors (FAPI) as a novel radiopharmaceutical targeting cancer-associated fibroblasts for the diagnosis and treatment of patients with Cancer of Unknown Primary: the FAPI-CUP trial
Purpose:
The FAPI-CUP trial seeks to address the unmet need for more effective diagnosis and treatment options for people with Cancer of Unknown Primary (CUP). We will investigate the role of a protein called Fibroblast Activation Protein (FAP). We will test whether using a new type of PET scan that looks for whether or not cancer cells are expressing FAP will help us to find the primary cancer in patients with CUP. We will also test a new type of treatment using a radionuclide therapy that targets FAP.
GO ID:
GO Title:
MRFF Clinical Trials Activity - RCRDUN Initiative – 2019 Rare Cancers, Rare Diseases and Unmet Need Grant Opportunity
Internal Reference ID:
MRF1200038
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Melbourne
Recipient ABN:
84 002 705 224
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
Country:
AUSTRALIA